Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.

Cancer cell - 13 Jul 2026

Alonso Salvador, Chu Kevan, Granowsky Elizabeth, Rabanales Valeria Saraiba, Parsons Marie J, Gunasinghe Himari, Shia Jinru, Yaeger Rona, Dow Lukas E

Abstract excerpt

KRAS is mutationally activated in 45%-50% of colorectal cancer (CRC) cases, and while KRAS-targeted therapies have shown clinical promise, drug resistance limits their efficacy. To explore the mechanisms underlying KRAS inhibitor resistance, we use targeted exome sequencing and spatial transcriptomics on patient-matched CRC biopsies following combined treatment with KRASG12C and EGFR inhibitors. We show that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 42167227
DOI: 10.1016/j.ccell.2026.04.009
PMCID: PMC13417870

Genes

KRAS
EGFR
TBK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.PMID 42167227Read ↗

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCSemantic proximity Read ↗

Molecular Profiling and High-Content Drug Screening of Metastatic Colorectal Cancer Organoids Reveal Evolutionary Mechanisms of Pan-KRAS Inhibitor ResistanceSemantic proximity Read ↗

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read ↗

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer.Semantic proximity Read ↗

Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor linesSemantic proximity Read ↗

An oncogenic phenoscape of colonic stem cell polarizationSemantic proximity Read ↗

One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling.Semantic proximity Read ↗

Epigenetic evolution of colorectal cancer and its microenvironment reveals new vulnerabilitiesSemantic proximity Read ↗

A Single-Cell Atlas of Liver Metastases of Colorectal Cancer Reveals the Reprogramming of the Tumor Microenvironment in Response to Preoperative ChemotherapySemantic proximity Read ↗

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read ↗

Multi-omics, organoid-based modeling reveals an SRC/mTOR-dependent fetal-like stem cell trajectory in colorectal cancerSemantic proximity Read ↗

Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.